Israel M - Search Results

1

Clinical pharmacology of continuous infusion doxorubicin.

Sweatman TW, Lokich JJ, Israel M. Sweatman TW, et al. Among authors: israel m. Ther Drug Monit. 1989;11(1):3-9. doi: 10.1097/00007691-198901000-00002. Ther Drug Monit. 1989. PMID: 2911850 Clinical Trial.

2

Pharmacology of N,N-di(n-butyl)adriamycin-14-valerate in the rat.

Han G, Israel M, Seshadri R, Dalton JT, Sweatman TW. Han G, et al. Among authors: israel m. Cancer Chemother Pharmacol. 1996;37(5):472-8. doi: 10.1007/s002800050414. Cancer Chemother Pharmacol. 1996. PMID: 8599871

3

Pharmacology of N-benzyladriamycin-14-valerate in the rat.

Sweatman TW, Seshadri R, Israel M. Sweatman TW, et al. Among authors: israel m. Cancer Chemother Pharmacol. 1999;43(5):419-26. doi: 10.1007/s002800050917. Cancer Chemother Pharmacol. 1999. PMID: 10100599

4

Pharmacologic rationale for intravesical N-trifluoroacetyladriamycin-14-valerate (AD 32): a preclinical study.

Sweatman TW, Parker RF, Israel M. Sweatman TW, et al. Among authors: israel m. Cancer Chemother Pharmacol. 1991;28(1):1-6. doi: 10.1007/BF00684948. Cancer Chemother Pharmacol. 1991. PMID: 2040028

5

Cytotoxicity and intracellular biotransformation of N-benzyladriamycin-14-valerate (AD 198) are modulated by changes in 14-O-acyl chain length.

Lothstein L, Rodrigues PJ, Sweatman TW, Israel M. Lothstein L, et al. Among authors: israel m. Anticancer Drugs. 1998 Jan;9(1):58-66. doi: 10.1097/00001813-199801000-00007. Anticancer Drugs. 1998. PMID: 9491793

6

Pilot study of the tolerability and toxicity of intravesical valrubicin immediately after transurethral resection of superficial bladder cancer.

Patterson AL, Greenberg RE, Weems L, Bahnson R, Wajsman Z, Israel M, Sweatman T, Webber D, Gulfo J. Patterson AL, et al. Among authors: israel m. Urology. 2000 Aug 1;56(2):232-5. doi: 10.1016/s0090-4295(00)00654-3. Urology. 2000. PMID: 10925084 Clinical Trial.

7

Anthracycline drug targeting: cytoplasmic versus nuclear--a fork in the road.

Lothstein L, Israel M, Sweatman TW. Lothstein L, et al. Among authors: israel m. Drug Resist Updat. 2001 Jun;4(3):169-77. doi: 10.1054/drup.2001.0201. Drug Resist Updat. 2001. PMID: 11768330 Review.

8

N-benzyladriamycin-14-valerate versus progressively doxorubicin-resistant murine tumours: cellular pharmacology and characterisation of cross-resistance in vitro and in vivo.

Ganapathi R, Grabowski D, Sweatman TW, Seshadri R, Israel M. Ganapathi R, et al. Among authors: israel m. Br J Cancer. 1989 Dec;60(6):819-26. doi: 10.1038/bjc.1989.373. Br J Cancer. 1989. PMID: 2605093 Free PMC article.

9

Amelioration of adriamycin toxicity through modification of drug-DNA binding properties.

Israel M, Seshadri R, Koseki Y, Sweatman TW, Idriss JM. Israel M, et al. Cancer Treat Rev. 1987 Dec;14(3-4):163-7. doi: 10.1016/0305-7372(87)90003-x. Cancer Treat Rev. 1987. PMID: 3440247 No abstract available.

10

Resistance to N-benzyladriamycin-14-valerate in mouse J774.2 cells: P-glycoprotein expression without reduced N-benzyladriamycin-14-valerate accumulation.

Lothstein L, Sweatman TW, Dockter ME, Israel M. Lothstein L, et al. Among authors: israel m. Cancer Res. 1992 Jun 15;52(12):3409-17. Cancer Res. 1992. PMID: 1350753

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

709 results

Search Page

Filters